UCLA ALZHEIMERS DISEASE RESEARCH CENTER

加州大学洛杉矶分校阿尔茨海默病研究中心

• 批准号: 8171019
• 负责人: JEFFREY L. CUMMINGS
• 金额: $ 0.3万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8171019
• 关键词: African American; Alzheimer' s Disease; Alzheimer' s disease model; Amyloid; Amyloid deposition; Antibodies; Apolipoproteins; Award; Basic Science; Behavioral; Brain; Clinical; Computer Retrieval of Information on Scientific Projects Database; DNA Library; Data; Databases; Dementia; Diagnosis; Dimensions; Doctor of Philosophy; Education; Frontotemporal Dementia; Funding; Genetic; Genotype; Goals; Grant; Hispanics; Image; Image Analysis; Inflammation; Infusion procedures; Institution; Investigation; Lewy Body Disease; Medical center; Olives - dietary; Patients; Pilot Projects; Population; Publications; Publishing; Research; Research Personnel; Resources; Role; Scientist; Signal Transduction; Source; Techniques; Tissues; Toxic effect; United States National Institutes of Health; Vascular Dementia; Vascular Diseases; abstracting; clinical research site; follow-up; image archival system; medical schools; neuropathology; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This application proposes the establishment of an Alzheimer's Disease Research Center (ADRC) at UCLA. The theme of the ADRC is "understanding the mechanisms and optimizing the treatment of Alzheimer's disease". An ADRC would add a basic science dimension to established activities of the current UCLA Alzheimer's Disease Core Center (ADCC), use tissues and antibodies from the ADCC Neuropathology Core, and facilitate an invigorating interchange between clinical scientists and the growing cadre of basic scientists at UCLA. The ADCC has accomplished its original goals and established a flow of well characterized patients that are being followed longitudinally (Clinical Core); accessioned 148 brains into the ADCC brain bank (Neuropathology Core); created an imaging archive with sophisticated image analysis techniques available to investigators (Imaging Subcore of Imaging and Genetics Core); developed mechanisms for routine genotyping and established a DNA bank for genetic investigations (G enetics Subcore of Imaging and Genetics Core); and engaged more than 3600 clinicians in educational programs (Education/Information Transfer Core). The ADCC database contains information on 1261 patients and controls, and in the past year we have achieved an annualized follow-up rate of 90%. In the past 5 years, we have awarded funding for 12 Pilot Projects; these projects have contributed to 10 funded grants and 22 publications. The ADCC has three clinical sites, each serving a different ethnic population: UCLA (primarily majority culture patients), Martin Luther King Medical Center/Drew Medical School (primarily an African-American population), and Olive View Medical Center (an Hispanic population). UCLA investigators using data from the Cores have advanced understanding of frontotemporal dementias, dementia with Lewy bodies, behavioral aspects of AD, the role of vascular disease in AD and vascular dementia, and the role of imaging and genetics in the diagnosis and characterizatio n of AD. ADCC investigators published 375 articles and 338 abstracts on dementia-related topics between 1993 and 1997. Three basic science projects are being proposed: 1) apolipoprotein influences on amyloid deposition (Greg Cole, Ph.D.), 2) amyloid deposition, toxicity, and inflammation in an amyloid infusion model of AD )Sally Frautschy, Ph.D.) and intracellular amyloid signaling (Istvan Mody, Ph.D.). The activities of the Cores will be continued an expanded in the ADRC and the Project Leaders will be integrated into all aspects of the ADRC.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本申请提出在UCLA建立阿尔茨海默病研究中心（ADRC）。ADRC的主题是“了解阿尔茨海默病的机制并优化治疗”。ADRC将为目前加州大学洛杉矶分校阿尔茨海默病核心中心（ADCC）的既定活动增加一个基础科学维度，使用ADCC神经病理学核心的组织和抗体，并促进临床科学家与加州大学洛杉矶分校不断增长的基础科学家之间的令人振奋的交流。ADCC已经实现了其最初的目标，并建立了一个良好的特征，正在进行纵向跟踪的患者流（临床核心）;将148个大脑纳入ADCC脑库（神经病理学核心）;创建了一个具有复杂图像分析技术的成像档案，可供研究者使用（成像和遗传学核心的成像子核心）;开发了常规基因分型机制，并建立了用于遗传调查的DNA库（成像和遗传学核心的遗传学子核心）;并在教育计划（教育/信息传输核心）中雇用了3600多名临床医生。ADCC数据库包含1261名患者和对照的信息，在过去的一年里，我们的年随访率达到了90%。在过去5年中，我们为12个试点项目提供了资金;这些项目为10个资助赠款和22个出版物做出了贡献。ADCC有三个临床站点，每个站点服务于不同的种族人群：UCLA（主要是多数文化患者），马丁路德金医学中心/德鲁医学院（主要是非洲裔美国人）和Olive View医学中心（西班牙裔人口）。加州大学洛杉矶分校的研究人员使用来自Cores的数据，对额颞叶痴呆、路易体痴呆、AD的行为方面、血管疾病在AD和血管性痴呆中的作用以及成像和遗传学在AD诊断和表征中的作用有了深入的了解。ADCC研究人员在1993年至1997年期间发表了375篇关于痴呆相关主题的文章和338篇摘要。三个基础科学项目正在提出：1）载脂蛋白对淀粉样蛋白沉积的影响（Greg科尔，博士），2)AD的淀粉样蛋白输注模型中的淀粉样蛋白沉积、毒性和炎症）Sally Frautschy，Ph.D.）和细胞内淀粉样蛋白信号传导（Istvan Mody，Ph.D.）。核心的活动将在ADRC中继续并扩大，项目领导人将融入ADRC的各个方面。